You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Focus on Nivolumab in NSCLC
|
|---|---|
| Published in |
Frontiers in Medicine, December 2016
|
| DOI | 10.3389/fmed.2016.00067 |
| Pubmed ID | |
| Authors |
Diego L. Cortinovis, Stefania Canova, Marida Abbate, Francesca Colonese, Paolo Bidoli |
| Abstract |
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immune-mediated adverse events, and how to overcome the immunoresistance. The aim of this review is to analyze literature data on nivolumab in lung cancer with a focus on critical aspects related to the drug in terms of safety, the use in clinical practice, and possible placement in the treatment algorithm. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hong Kong | 1 | 20% |
| France | 1 | 20% |
| Switzerland | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 26% |
| Student > Master | 6 | 16% |
| Researcher | 5 | 13% |
| Student > Doctoral Student | 3 | 8% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 45% |
| Biochemistry, Genetics and Molecular Biology | 5 | 13% |
| Agricultural and Biological Sciences | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 12 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 December 2016.
All research outputs
#6,817,336
of 22,912,409 outputs
Outputs from Frontiers in Medicine
#1,517
of 5,708 outputs
Outputs of similar age
#124,993
of 420,158 outputs
Outputs of similar age from Frontiers in Medicine
#10
of 34 outputs
Altmetric has tracked 22,912,409 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 5,708 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.0. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,158 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.